SpectraScience, Inc. (SCIE)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0000 - Volume
10,000 - Avg. Volume
1,778,980 - Market Cap (intraday)
223 - Beta (5Y Monthly) -18.16
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0050 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. It offers WavSTAT3 optical biopsy system to determine whether a colon tissue is normal, pre-cancerous, or cancerous without physically removing tissue from the body; and WavSTAT4 optical biopsy system, a colon diagnostic product that operates by using UV laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer. The company also sells mobile consoles and disposable forceps. In addition, it engages in developing an esophageal diagnosis application for the detection of pre-cancerous and cancerous tissues in various tissues of the body. The company was formerly known as GV Medical, Inc. and changed its name to SpectraScience, Inc. in October 1992. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California.
www.spectrascience.com5
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: SCIE
Performance Overview: SCIE
Trailing total returns as of 5/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SCIE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SCIE
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-92.47%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.35M
Diluted EPS (ttm)
-0.0050
Balance Sheet and Cash Flow
Total Cash (mrq)
27.88k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
746.39k
Research Analysis: SCIE
Company Insights: SCIE
SCIE does not have Company Insights